JP7437576B2 - 乳癌および前立腺癌の処置のための組成物 - Google Patents

乳癌および前立腺癌の処置のための組成物 Download PDF

Info

Publication number
JP7437576B2
JP7437576B2 JP2020550040A JP2020550040A JP7437576B2 JP 7437576 B2 JP7437576 B2 JP 7437576B2 JP 2020550040 A JP2020550040 A JP 2020550040A JP 2020550040 A JP2020550040 A JP 2020550040A JP 7437576 B2 JP7437576 B2 JP 7437576B2
Authority
JP
Japan
Prior art keywords
seviteronel
amount
dexamethasone
range
study
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020550040A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021505669A (ja
JP2021505669A5 (https=
Inventor
バスキン－ベイ，エドウィナ
アイズナー，ジョエル
ウッドソン，エリザベス
Original Assignee
ケンビ セラピューティクス ピーティーワイ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ケンビ セラピューティクス ピーティーワイ リミテッド filed Critical ケンビ セラピューティクス ピーティーワイ リミテッド
Publication of JP2021505669A publication Critical patent/JP2021505669A/ja
Publication of JP2021505669A5 publication Critical patent/JP2021505669A5/ja
Application granted granted Critical
Publication of JP7437576B2 publication Critical patent/JP7437576B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020550040A 2017-12-07 2018-12-06 乳癌および前立腺癌の処置のための組成物 Active JP7437576B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762595918P 2017-12-07 2017-12-07
US62/595,918 2017-12-07
PCT/US2018/064229 WO2019113301A1 (en) 2017-12-07 2018-12-06 Compositions for the treatment of breast and prostate cancer

Publications (3)

Publication Number Publication Date
JP2021505669A JP2021505669A (ja) 2021-02-18
JP2021505669A5 JP2021505669A5 (https=) 2022-01-11
JP7437576B2 true JP7437576B2 (ja) 2024-02-26

Family

ID=66750338

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020550040A Active JP7437576B2 (ja) 2017-12-07 2018-12-06 乳癌および前立腺癌の処置のための組成物

Country Status (8)

Country Link
US (2) US20210292410A1 (https=)
EP (1) EP3720427A4 (https=)
JP (1) JP7437576B2 (https=)
CN (1) CN111698985B (https=)
AU (1) AU2018380155B2 (https=)
CA (1) CA3084997A1 (https=)
TW (1) TWI809015B (https=)
WO (1) WO2019113301A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12358983B2 (en) 2016-10-28 2025-07-15 Incyte Corporation Combination of anti CD19 antibody with a BCL-2 inhibitor and uses thereof
US12357615B2 (en) 2018-10-11 2025-07-15 Kembi Therapeutics Pty Ltd Compositions for the treatment of brain tumors
CA3158748A1 (en) * 2019-10-25 2021-04-29 Garvan Institute Of Medical Research Methods of treating cancer using androgen receptor antagonists
US12150776B2 (en) * 2021-04-26 2024-11-26 Wisconsin Alumni Research Foundation & AIQ Solutions, Inc. System and method for monitoring multiple lesions

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4921475A (en) 1983-08-18 1990-05-01 Drug Delivery Systems Inc. Transdermal drug patch with microtubes
US5087240A (en) 1983-08-18 1992-02-11 Drug Delivery Systems Inc. Transdermal drug patch with conductive fibers
US4738851A (en) 1985-09-27 1988-04-19 University Of Iowa Research Foundation, Inc. Controlled release ophthalmic gel formulation
US5163899A (en) 1987-03-20 1992-11-17 Drug Delivery Systems Inc. Transdermal drug delivery system
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
GB8804164D0 (en) 1988-02-23 1988-03-23 Tucker J M Bandage for administering physiologically active compound
US4882150A (en) 1988-06-03 1989-11-21 Kaufman Herbert E Drug delivery system
US5008110A (en) 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
US5088977A (en) 1988-12-21 1992-02-18 Drug Delivery Systems Inc. Electrical transdermal drug applicator with counteractor and method of drug delivery
US5521222A (en) 1989-09-28 1996-05-28 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
DK0431519T3 (da) 1989-12-04 1994-07-04 Searle & Co System til transdermal indgivelse af albuterol
US5077033A (en) 1990-08-07 1991-12-31 Mediventures Inc. Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide
JP2594486B2 (ja) 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
ATE132381T1 (de) 1992-01-29 1996-01-15 Voelkl Franz Ski Ballspielschläger, insbesondere tennisschläger
IL114193A (en) 1994-06-20 2000-02-29 Teva Pharma Ophthalmic pharmaceutical compositions based on sodium alginate
ES2094688B1 (es) 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
IT1283911B1 (it) 1996-02-05 1998-05-07 Farmigea Spa Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo
US5800807A (en) 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
US6261547B1 (en) 1998-04-07 2001-07-17 Alcon Manufacturing, Ltd. Gelling ophthalmic compositions containing xanthan gum
US6197934B1 (en) 1998-05-22 2001-03-06 Collagenesis, Inc. Compound delivery using rapidly dissolving collagen film
CA2755976C (en) 2009-03-23 2020-04-07 Ambit Biosciences Corporation Methods of treatment using combination therapy
KR101848077B1 (ko) * 2010-11-13 2018-04-11 이노크린 파마슈티컬즈, 인크. 금속효소 억제제 화합물
EP2751117A4 (en) * 2011-08-30 2015-06-24 Innocrin Pharmaceuticals Inc METALLOENZYMHEMMERVERBINDUNGEN
US20150005265A1 (en) * 2011-12-22 2015-01-01 Susan Stewart Methods and compositions for combination therapy using p13k/mtor inhibitores
PL2945628T3 (pl) * 2013-01-15 2020-09-21 Aragon Pharmaceuticals, Inc. Modulator receptorów androgenowych w skojarzeniu z octanem abirateronu i prednizonem do leczenia nowotworu stercza

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Asian Journal of Andrology，2014年，Vol. 16，pp. 387-400
Bioorganic & Medicinal Chemistry Letters，2014年，Vol. 24，pp. 2444-2447
BJC，2014年，Vol. 111，pp. 2248-2253
医薬品情報学，2010年，Vol. 11, No. 4，pp. 217-222 (9-14)

Also Published As

Publication number Publication date
JP2021505669A (ja) 2021-02-18
CN111698985B (zh) 2023-10-31
TWI809015B (zh) 2023-07-21
WO2019113301A1 (en) 2019-06-13
US20210154209A1 (en) 2021-05-27
AU2018380155B2 (en) 2024-07-04
CA3084997A1 (en) 2019-06-13
EP3720427A4 (en) 2021-09-15
CN111698985A (zh) 2020-09-22
AU2018380155A1 (en) 2020-07-02
US20210292410A1 (en) 2021-09-23
US11980626B2 (en) 2024-05-14
TW201938157A (zh) 2019-10-01
EP3720427A1 (en) 2020-10-14

Similar Documents

Publication Publication Date Title
JP7437576B2 (ja) 乳癌および前立腺癌の処置のための組成物
JP6701407B2 (ja) バルドキソロンメチルまたはその類似体を使用して内皮機能障害を処置および予防する方法
US9216221B2 (en) Medicament and method of diagnosis for treating subclinical Cushing's syndrome
US20250375446A1 (en) Methods of treating chronic spontaneous urticaria using a bruton's tyrosine kinase inhibitor
JP2023179435A (ja) 多発性骨髄腫治療
US20230039711A1 (en) Ahr inhibitors and uses thereof
EP3908279B1 (en) Lta4h inhibitor for the treatment or prevention of hidradenitis suppurativa
US20200345746A1 (en) Oxazine Derivative for Use in the Prevention of Alzheimer's Disease in at Risk Patents
CN111033634A (zh) 用于治疗纤维化疾病的化合物及其药物组合物
US20250381179A1 (en) Chroman-based compounds for treating cancer
MX2014012001A (es) Metodos para tratar el cancer usando inhibidor de pi3k e inhibidor de mek.
US11149300B1 (en) Methods of treating gastrointestinal malignancies
KR20190068567A (ko) 뇌 아밀로이드 혈관병증의 치료 또는 예방에 사용하기 위한 옥사진 유도체
WO2012119010A9 (en) Materials for inhibiting aromatase and method of using the same to diagnose, treat and monitor breast cancer
HK40126655A (en) Methods of treating chronic spontaneous urticaria using a bruton s tyrosine kinase inhibitor
TW202513060A (zh) 用於降低心血管疾病的風險之nlrp3抑制劑
WO2024076633A1 (en) Methods of treating estrogen receptor-mediated disorders
EP4561574A1 (en) Dosing regimen for a nlrp3 inhibitor
WO2021078937A1 (en) Treatment of stat3 related diseases by iron chelators
HK40061328B (en) A bruton's tyrosine kinase inhibitor for use in the treatment of chronic spontaneous urticaria
HK40061328A (en) A bruton's tyrosine kinase inhibitor for use in the treatment of chronic spontaneous urticaria

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211130

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221025

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230123

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230314

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230613

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230620

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20230713

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230718

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230821

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240122

R150 Certificate of patent or registration of utility model

Ref document number: 7437576

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150